Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab + IBI310 + Chemotherapy as Neoadjuvant Therapy for Stage II-III NSCLC
NCT07410975Phase 2Recruiting
- Sponsor
- Shanghai Pulmonary Hospital
- Start
- Jan 2026
- Primary completion
- Jun 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of IBI310 in non-small cell lung cancer (NSCLC), sponsored by Shanghai Pulmonary Hospital. Primary endpoint: Major Pathologic Response Rate at 5 months. Started Jan 2026; status: recruiting.
02
Drugs
IBI310
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07410975.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07410975.